What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk
Binder's disposition followed vesting of performance-based awards tied to the company's total shareholder return relative to the Russell 3000 Pharmaceutical & Biotechnology Index.